Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
alemtuzumab (campath) (1 trial)
allogeneic hematopoietic stem cells (Hemacord) (1 trial)
asparaginase (elspar) (2 trials)
autologous hematopoietic stem cells (1 trial)
cyclophosphamide (cytoxan) (2 trials)
daunorubicin (cerubidine) (2 trials)
etoposide (vepesid) (1 trial)
fludarabine (fludara) (2 trials)
idarubicin (idamycin) (1 trial)
imatinib (gleevec) (1 trial)
lenalidomide (revlimid) (1 trial)
mercaptopurine (purinethol) (2 trials)
methylprednisolone (medrol) (2 trials)
mitoxantrone (novantrone) (1 trial)
naltrexone (revia) (2 trials)
prednisone (meticorten) (2 trials)
vincristine (oncovin) (2 trials)
cytarabine (cytosar-u) (1 trial)
doxorubicin (Doxil) (1 trial)
ifosfamide (ifex) (1 trial)
tioguanine (Lanvis) (1 trial)
urea (1 trial)
Leukemia (Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Leukemia, Lymphoid (Phase 2)
Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)
Trials (4 total)
Trial APIs (22 total)